Approval · Notice of Compliance 37166 · 2026
MIRAPEX: Notice of Compliance 37166
Issued March 24, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37166
- Date
- March 24, 2026
- Company
- Boehringer Ingelheim (Canada) Ltd.Burlington, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of a drug product manufacturing site and/or manufacturer involving production. Addition of a drug product manufacturing site and/or manufacturer involving primary packaging. Change in the specification for the drug product
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MIRAPEX | Not yet assigned | — |
Medicinal ingredients
- PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 0.25 MG per TAB
- PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 0.125 MG per TAB